Hepatitis C Virus Market Will Expand Dramatically From $2 Billion in 2008 to Nearly $7.7 Billion in 2013
Posted on: Monday, 22 June 2009, 08:00 CDT
Roche and Schering-Plough Will Continue to be Prominent Players in the Market, According to a New Report from Decision Resources
The new Pharmacor report entitled Hepatitis C Virus finds that, through 2013, robust market growth will be driven by the launches of novel hepatitis C virus-specific agents and an increase in the size of the drug-treated population. Roche and Schering-Plough will continue to be prominent players and a number of other companies -- including Johnson & Johnson and Pfizer -- will also carve out a share in the market.
The report also finds that the competitive hepatitis C virus pipeline is characterized by its significant commercial potential which is well-recognized by drug developers. Several agents in late-stage development -- most notably protease inhibitors such as Vertex/Johnson & Johnson/Mitsubishi Tanabe's telaprevir and Schering-Plough's boceprevir as well as polymerase inhibitors such as Roche/Pharmasset's R-7128 and Pfizer's filibuvir -- will drive market growth.
"The standard of care will change significantly with the introduction of new classes of hepatitis C virus-specific antiviral agents, such as protease inhibitors and polymerase inhibitors," said Decision Resources Analyst
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Decision Resources Decision Resources, Inc. Christopher Comfort Elizabeth Marshall 781-296-2597 781-296-2563 ccomfort@dresources.com emarshall@dresources.comSOURCE Decision Resources
Source: PR Newswire
Related Articles
- Driven by the Launch of Targeted Agents, the Gastric Cancer Drug Market Will More Than Double to Nearly $1.5 Billion in 2018
- Biologic Agents Will Drive the Systemic Lupus Erythematosus Drug Market to More Than Quadruple to Nearly $2 Billion in 2018
- Launch of Targeted Agents and Increased Use of Maintenance Therapy Will Drive the Non-Small-Cell Lung Cancer Drug Market to Nearly Triple to Almost $10 Billion in 2018
- For the Treatment of Rheumatoid Arthritis, Market Share for TNF-alpha Inhibitors Will Decrease Through 2018
- The Global Anti-Infective Market is Currently Valued at US $66.5 Billion With Antiviral Agents Accounting for 24% of Sales
- Market for Battery Cells Will Exceed US $9 Billion By 2010
- Abbott/Eisai's Humira and UCB's Cimzia Will Drive Sales of TNF-Alpha Inhibitors to $1.3 Billion in the Market to Treat Crohn's Disease
- Internal Relationship Management: Linking Human Resources to Market Performance
- New Paradigm Resources Group's New Fixed Wireless Carriers Report(TM) Finds Market Renaissance
- Analysys International Says China's Annual Online Learning Market Will Rebound to Reach RMB11.61 Billion in 2005
 |
 |
User Comments (0)
RSS Feeds